



<u>Procedure</u>	<u>Result</u>	<u>Units</u>	<u>Ref Interval</u>	<u>Accession</u>	<u>Collected</u>	<u>Received</u>	<u>Reported/</u> <u>Verified</u>
Chromogranin in serum	>1000000 H	ng/mL	[0-103]	20-155-900174	03-Jun-20 14:27:00	03-Jun-20 14:27:00	03-Jun-20 15:00:39

03-Jun-20 14:27:00 Chromogranin in serum:  
 INTERPRETIVE INFORMATION: Chromogranin A, Serum

This test is performed using the BRAHMS CGA II Kryptor kit. Results obtained with different methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

Nontumor-related elevations of Chromogranin A can be observed in gastrointestinal, cardiovascular, and renal disorders, as well as with proton pump inhibitor (PPI) therapy. It is recommended to stop PPI treatment for at least two weeks prior to testing. Moderate H2-receptor antagonist therapy does not lead to significant elevations of Chromogranin A.

See Compliance Statement D: www.aruplab.com/CS

\* Abnormal, # = Corrected, C = Critical, f = Footnote, H = High, L = Low, t = Interpretive Text, @ = Reference Lab